<DOC>
	<DOCNO>NCT02772822</DOCNO>
	<brief_summary>The primary objective study assess efficiency SCT400 plus CHOP versus Rituximab plus CHOP untreated CD20-positive DLBCL Patients . The secondary objective study evaluate safety SCT400 plus CHOP , well presence human anti-chimeric antibody ( HACA ) .</brief_summary>
	<brief_title>A Study Comparing Efficiency Safety S-CHOP ( Cyclophosphamide , Hydroxydaunomycin , Oncovin , Prednisone ) Versus R-CHOP Untreated CD20 ( Cluster Differentiation Antigen 20 ) -Positive DLBCL Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Untreated CD20positive DLBCL confirm local histopathology . 2. International Prognostic Index ( IPI ) score 0 2 : Score 0 need accompany bulky disease , define presence tumor mass diameter 7.5 cm . 3 . 18 year 70 year ; Male female patient . 4 . More 6 month life expectancy . 5 . At least one measurable lymph node : For nodal tumor mass , 1.5 cm long axis 1.0 cm short axis ; For extranodal tumor mass , 1.0 cm long axis . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 7 . Adequate cardiac function ( LVEF≥50 % ) . 8 . Adequate hematological function : absolute neutrophil count ( ANC ) ≥1.5*109/L platelet count ( PLT ) ≥75*109/L . 9 . Fertile patient must use effective contraception treatment within 3 month treatment . 10 . Signed informed consent form approve institutional review board respective medical center . 1 . Known allergic reaction human murine monoclonal antibody , murine product , foreign protein . 2 . Known allergic reaction component CHOP regimen . 3 . Previous treatment DLBCL , include chemotherapy , immunotherapy , partial radiotherapy lymphoma , monoclonal antibody therapy surgical treatment ( exclude lymph node biopsy surgical resection nonlymphoma lesion ) . 4 . History cytotoxic drug treatment antiCD20 monoclonal antibody treatment disease ( e.g. , rheumatoid arthritis ) , prior use monoclonal antibody within 3 month . 5 . Primary central nervous system ( CNS ) lymphoma , secondary CNS involvement , grey zone lymphoma ( GZL ) burkitt DLBCL , primary effusion lymphoma , plasmablastic lymphoma , primary cutaneous DLBCL , anaplastic lymphoma kinase ( ALK ) positive DLBCL transform lymphoma . 6 . History cancer within past 5 year except cure basal cell skin cancer , squamous cell carcinoma , cutaneous melanoma carcinoma situ cervix . 7 . Patients significant cardiac disease , include heart disease grade Ⅲ Ⅳ accord New York Heart Association ( NYHA ) system , occurrence myocardial infarction , unstable arrhythmia , unstable angina severe hypertension past 6 month peripheral nervous system ( PNS ) CNS disease . 8 . Previously suffer progressive multifocal leukoencephalopathy . 9 . Having continuous treatment corticosteroid drug last 10 day : Prednisone dosage 30mg/day ; Other corticosteroid drug equal dosage . 10 . Participation another clinical trial past 3 month . 11 . Recent major surgery within 4 week . 12 . Use hemopoietic cytokine past 2 week , e.g . granulocyte colony stimulate factor ( GCSF ) . 13 . Vaccination attenuate live vaccine within 4 week . 14 . Abnormal laboratory value : Creatinine 1.5 time normal value ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2.5 time normal value ( 5 time hepatic involvement ) ; total bilirubin ( TBIT ) 1.5 time normal value ( 3 time hepatic involvement ) ; Without anticoagulant therapy , partial thromboplastin time ( PTT ) , activate partial thromboplastin time ( APTT ) international normalize ratio ( INR ) 1.5 time normal value . 15 . Active Infectious disease significant infection require intravenous antibiotic therapy hospitalization past 4 week ( exception tumor induce fever ) . 16 . Suspected active latent tuberculosis . 17 . Seropositive human immunodeficiency virus ( HIV ) hepatitis C antibody . Hepatitis B virus ( HBV ) positive patient ( include positive hepatitis B surface antigen positive hepatitis B virus core antibody ) may participate serum HBV DNA level sufficient low . 18 . Other disease symptom investigator 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>